# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant...
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normaliz...
Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...